Skip to main content

Table 1 Maternal and infant safety outcomes of artemether and lumefantrine use during pregnancy

From: A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy

Publication

Drug (n)

Trimester

Maternal outcomes

Infant outcomes

1

2/3

AE

SAE

Death

Normal development

Death, 1 yr

Wang 1989[20]

A

0

2

   

2/2a

 

Sowunmi et al., 1998[15]

A + MQ (22), A (23)

0

45

Minimal

  

Yesb

 

McGready et al. , 2001[17]

A + MQ/AS/C (10), AL (1)

–

–

 

0/9c

1/9d

  

Adam et al., 2004[16]

A

1

27

  

0/28

  

McGready et al., 2006[21]

AL

0

13*

 

0/13

 

9/10e

 

McGready et al. , 2008[22]

AL

0

125

 

1c,f

1g

 

1/117 (0.9%)h

AS

0

128

 

0c

0

 

8/120 (6.7%)i

Kaye et al. , 2008[23]

AL

0

58

7

    

Adam et al., 2009[24]

A (48), AL (3)

51

0

  

0

 

0/49

Piola et al. , 2010[25]

AL

0

152

94/152 (61.8%)j

 

0

  

Q

0

152

142/152 (93%)j

 

1k

  

Manyando et al. , 2010[26]

ALl

156

348

 

108/495 (21.8%)

1 (0.2%)m

  

SP/Ql

138

378

 

SP 118/506 (23.3%)

5 (1%)n

  

Sangaré et al., 2011[27]

AL (260)o

53p

207

     
  1. A artemether; AE adverse events; AL artemether-lumefantrine; AS artesunate; C clindamycin; IM intramuscular; MQ mefloquine; Q quinine; SAE serious adverse event; SP sulphadoxine-pyrimethamine; *These 13 exposures are not included in the total count of exposures to AL in pregnant women as they were also included in McGready, et al. 2008 [22]; a5 years; bphysical and neurodevelopment within normal limits (6–36 months); cdrug related; dsevere malaria and anaemia; e1 year; fDay 2 increase in parasitaemia; ghaemorrhagic shock (treatment not suspected); hsuspected intraventricular haemorrhage, background of Allagile’s syndrome; i3 related to prematurity, 2 pneumonia, 1 sepsis, 1 diarrhoea, 1 suspected beriberi; jnumber reporting at least 1 AE; ksepsis following a caesarean section; lAL group n = 495, AL exposure n = 504, SP group n = 506, SP/Q exposure n = 516; manaemia secondary to spontaneous abortion; n1 related to Kaposi’s sarcoma, 3 infections, 1 undiagnosed illness; o260 reports of AL treatment for an episode of malaria; p26 received only AL in the 1st trimester.